State-of-the-Art-Review : Thrombogenesis in Myocardial Infarction and Related Syndromes: The Role of Molecular Markers in Diagnosis and Management

Abstract

References

Antman EM , Braunwald E. Acute myocardial infarction. In: Braunwald E , ed. Heart disease. Philadelphia: W.B. Saunders Co., 1995:1184.

Willerson JT Conversion from chronic to acute coronary heart disease syndromes: role of platelets and platelet products. Tex Heart Inst J 1995;22:13.

National Heart Attack Alert Program: Emergency Department: rapid identification and treatment of patients with acute myocardial infarction (NIH Publication 93-3278). Bethesda, MD, National Heart, Lung and Blood Institute , 1993.

Pfeffer M. ACE inhibition in acute myocardial infarction. N Engl J Med 1995;332:118.

Herrick JB Clinical features of sudden obstruction of the coronary arteries. JAMA 1912;23:2015.

The Timi IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994;89:1545.

Fareed J. Current trend in antithrombotic and device development. Semin Thromb Hemost 1996;22:3.

Blann AD , Lip Gyh , Beavers DG , McCollum CN Soluble p-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Hemost Thromb 1997;25:1077.

Hearse DJ , Bolli R. Reperfusion induced injury: manifestations, mechanisms and clinical relevance . Cardiovasc Res 1992;26:101.

10.

Topol EJ , Ellis SG Coronary collaterals revisited: accessory pathway to myocardial preservation during infarction. Circulation 1991;83:1084.

11.

Gumina RJ , Newman PJ , Kenny D. , et al. The leukocyte cell adhesion cascade and its role in myocardial ischemia-reperfusion injury. Bas Res Cardiol 1997;92:201.

12.

Albelda SM , Muller WA , Buck CA , Newman PJ Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 1991 ;114:1059.

13.

Engler RL , Dahlgren MD , Morris DD , et al. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 1986;251:H314.

14.

Lorant DE , McEver RP , McIntyre TM , et al. Activation of polymorphonuclear leukocytes reduces their adhesion to p-selectin and causes redistribution of ligands for p-selectin on their surfaces. J Clin Invest 1995;96:171.

15.

Topol EJ Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995;75:27B.

16.

Amiral J. , Fareed J. Thromboembolic diseases: Biochemical mechanisms and new possibilities of biological diagnosis. Semin Thromb Hemost 1996;22:41.

17.

Broze G. , Miletich JP Characterization of the inhibition of tissue factor in serum. Blood 1987;69:150.

18.

Broze G. , Warren J. , Novotny LA , et al. The lipoprotein associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex also inhibits factors Xa: insight into its possible mechanism of action. Blood 1988 ;71:335.

19.

Bauer KA , Rosenberg RD The pathophysiology of the prothrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987;70:343-350.

20.

Messmore HL , Walenga JM , Fareed J. Molecular markers of platelet activation. Semin Thromb Hemost 1984;10:264.

21.

Reddy VE , Kowal-Vern A. , Hoppensteadt D. , et al. Global and molecular hemostatic markers in acute myeloid leukemia . Am J Clin Pathol 1990;4:397.

22.

Aurousseau MH , Amiral J. , Boffa MC Level of plasma thrombomodulin in neonates and children. (Abstract 1937). Thromb Haemost 1991;65:1232.

23.

Stephens Cjm. The antiphospholipid syndrome. Clinical correlations, cutaneous features, mechanism of thrombosis and treatment of patients with the lupus anticoagulant and anticardiolipin antibodies. Br J Dermatol 1991;125:199.

24.

Walenga JM , Hoppensteadt D. Automation in hemostasis. In: Schoeff LE , Williams RH , eds. Principles of laboratory instruments. St. Louis: Mosby Year Book, Inc., 1993;379.

25.

Fareed J. , Walenga JM , Baker WH , et al. Molecular markers of hemostatic activation in atherosclerosis: a new concept in diagnostic profiling of endogenous pathophysiologic transition . Semin Thromb Hemost 1986;12:102.

26.

Fareed J. , Walenga JM Changing trends in hemostatic testing. In: Automation and new technology in the clinical laboratory. Oxford: Blackwell Scientific, 1990;203.

27.

Fareed J. , Baker WH , Walenga JM , et al. Molecular markers of hemostatic activation: future perspectives . Semin Thromb Hemost 1984;10:329.

28.

Amiral J. , Adalbert B. , Adam M. Application of enzyme immunoassays to coagulation testing. Clin Chem 1984;30:1512.

29.

Fareed J. , Moncada R. , Messmore HL , et al. Molecular markers of contrast media-induced adverse reactions . Semin Thromb Hemost 1984;10:306-326.

30.

Fareed J. , Walenga JM , Saravia G. , et al. Thrombogenic potential of nonionic contrast media. Radiology 1990;174:321.

31.

Lewy RI , Weiner L. , Smith JB , et al. Detection of plasma concentrations of thromboxane B2 in Prinzmetal's variant angina and clinical angina pectoris. Clin Cardiol 1979;2:404.

32.

Hoppensteadt D. , Fareed J. , Walenga JM , et al. Measurement of functional and immunologic levels of tissue factor pathway inhibitor: some methodologic considerations . Blood 1993;82:2458.

33.

Cohen MC , Demers C. , Gurfinkel EP , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable angina coronary artery disease. N Engl J Med 1997;337:447.

34.

Fareed J. , Messmore HL Plasma thrombomodulin level as predictor of hemorrhagic (and thrombotic) events in patients on longterm anticoagulant treatment. Circulation 1997;96:2765.

35.

Grassman ED , Leya F. , Lewis B. , et al. The low molecular weight heparin certoparin may significantly prevent restenosis following balloon coronary angioplasty . Circulation 1997;96:1132.